BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9006095)

  • 1. Absence of p16/MTS1 gene mutations in human prostate cancer.
    Chen W; Weghorst CM; Sabourin CL; Wang Y; Wang D; Bostwick DG; Stoner GD
    Carcinogenesis; 1996 Dec; 17(12):2603-7. PubMed ID: 9006095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
    Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
    Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
    Ogawa S; Hangaishi A; Miyawaki S; Hirosawa S; Miura Y; Takeyama K; Kamada N; Ohtake S; Uike N; Shimazaki C
    Blood; 1995 Aug; 86(4):1548-56. PubMed ID: 7632963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
    Sonoda Y; Yoshimoto T; Sekiya T
    Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of the p16 gene in human neuroblastomas.
    Castresana JS; Gómez L; García-Miguel P; Queizán A; Pestaña A
    Mol Carcinog; 1997 Mar; 18(3):129-33. PubMed ID: 9115582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.
    Heidenreich B; Heidenreich A; Sesterhenn A; Srivastava S; Moul JW; Sesterhenn IA
    Eur Urol; 2000 Oct; 38(4):475-82. PubMed ID: 11025389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 mutations/deletions are not frequent events in prostate cancer.
    Tamimi Y; Bringuier PP; Smit F; van Bokhoven A; Debruyne FM; Schalken JA
    Br J Cancer; 1996 Jul; 74(1):120-2. PubMed ID: 8679444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
    Raffel C; Ueki K; Harsh GR; Louis DN
    Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.
    Schuyer M; van Staveren IL; Klijn JG; vd Burg ME; Stoter G; Henzen-Logmans SC; Foekens JA; Berns EM
    Br J Cancer; 1996 Oct; 74(7):1069-73. PubMed ID: 8855976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
    Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
    Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
    Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
    Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
    Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of the p16/MTS1 gene without mutation is frequent in human urinary bladder carcinomas.
    Asamoto M; Iwahori Y; Okamura T; Shirai T; Tsuda H
    Jpn J Clin Oncol; 1997 Feb; 27(1):22-5. PubMed ID: 9070336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
    Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
    Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers.
    Okajima E; Fukuda T; Okita S; Tsutsumi M; Hirao Y; Okajima E; Konishi Y
    Cancer Lett; 1996 Jun; 103(2):227-31. PubMed ID: 8635161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood.
    Ohnishi H; Hanada R; Horibe K; Hongo T; Kawamura M; Naritaka S; Bessho F; Yanagisawa M; Nobori T; Yamamori S; Hayashi Y
    Leukemia; 1996 Jul; 10(7):1104-10. PubMed ID: 8683987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence.
    Friedrich MG; Blind C; Milde-Langosch K; Erbersdobler A; Conrad S; Löning T; Hammerer P; Huland H
    Eur Urol; 2001 Nov; 40(5):518-24. PubMed ID: 11752859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas.
    Sun Y; Hildesheim A; Lanier AE; Cao Y; Yao KT; Raab-Traub N; Yang CS
    Oncogene; 1995 Feb; 10(4):785-8. PubMed ID: 7862458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of the INK4 family of genes in prostate carcinomas.
    Park DJ; Wilczynski SP; Pham EY; Miller CW; Koeffler HP
    J Urol; 1997 May; 157(5):1995-9. PubMed ID: 9112579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.